Archive

Neovasc Announces Positive Interim Results from REDUCER-I Study

NASDAQ, TSX: NVCN   VANCOUVER and MINNEAPOLIS, June 26, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced positive interim results of the REDUCER-I study during the PCR E-Course. Stefan Verheye, M.D., PhD, ZNA Middelheim, Antwerp, Belgium presented the results of the trial during...

Read More

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

NASDAQ, TSX: NVCN   VANCOUVER and MINNEAPOLIS, June 25, 2020 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), announced that it received written notification yesterday (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum...

Read More

Neovasc Reducer™ Spotlighted in Leading German Public Television Program

Elective Interventional Procedures Resume in Germany   NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 3, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina,...

Read More